PLUS1
Best deals to access real time data! |
|
SMALL CAP BASIC
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
SMALL CAP PRO
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last: $ 29.05 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type | ISIN |
|---|---|---|---|---|
| Roche Holding (QX) | RHHBY | Other OTC | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| +0.33 | +1.15% | 29.05 | 29.09 | 28.85 | 28.91 | 28.72 | 16:35:32 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 29.01 | 29.05 | 0.04 | 0.14% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,569 | 2,347,232 | $ 28.9900 | $ 68.05M | 1.44M | 26.30 - 35.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:13 | formt | 737 | $29.05 | USD |
Roche Holding (QX) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 25.06B | 862.56M | $ 8.63B | - | 2.90 | 862.39M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Roche Holding (QX) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/26/2018 | 06:38 | Dow Jones News | Roche's Genentech Gets FDA Priority Review for Flu Drug |
| 6/25/2018 | 10:04 | Dow Jones News | AbbVie Gets FDA Priority Review for Imbruvica/Rituximab.. |
| 6/22/2018 | 01:52 | Dow Jones News | Roche to Appoint James Sabry as Head of Partnering |
| 6/20/2018 | 03:02 | Dow Jones News | Roche to Buy Rest of Cancer Firm -- WSJ |
| 6/19/2018 | 02:48 | Dow Jones News | Roche, Foundation Medicine Reach Definitive Merger Agreement.. |
| 6/19/2018 | 01:57 | Dow Jones News | Roche, Foundation Medicine Reach Definitive Merger Agreement |
| 6/15/2018 | 03:20 | Dow Jones News | Roche's Gazyva Cancer Drug Outperforms MabThera |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RHHBY Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Month | 26.57 | 29.09 | 26.35 | 27.5109 | 595k | 3M | 1M | 2.48 | 9.33% |
| 3 Months | 27.821 | 29.09 | 26.3 | 27.5982 | 427k | 4M | 1M | 1.229 | 4.42% |
| 6 Months | 31.61 | 31.79 | 26.3 | 28.8471 | 427k | 7M | 2M | -2.56 | -8.10% |
| 1 Year | 31.855 | 35.5 | 26.3 | 29.7786 | 290k | 12M | 2M | -2.805 | -8.81% |
| 3 Years | 36.44 | 36.82 | 0.000507 | 30.9682 | 240k | 12M | 1M | -7.39 | -20.28% |
| 5 Years | 30.79 | 38.71 | 0.000507 | 32.4651 | 42k | 12M | 1M | -1.74 | -5.65% |
Roche Holding (QX) Description
| Headquartered in Basel, Switzerland, Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2017, the Roche Group employed about 94,000 people worldwide, invested 10.4 billion Swiss francs in R&D and posted sales of 53.3 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com |
